Metacrine is a privately held biotech company ?founded in 2015 on technology licensed from the ?laboratory of Dr. Ronald Evans, a world leader in? nuclear hormone receptors and Howard Hughes?Medical Institute Investigator at the Salk Institute. Metacrine will leverage two mechanistically distinct programs to target diabetes, steatohepatitis and other metabolic and liver disorders.